BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10365143)

  • 1. Treosulfan in the treatment of metastatic renal cell carcinoma.
    Rigos D; Wechsel HW; Bichler KH
    Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alkylator treosulfan shows activity towards human renal-cell carcinoma in vivo and in vitro.
    Köpf-Maier P
    In Vivo; 1998; 12(3):275-88. PubMed ID: 9706471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
    Meden H; Wittkop Y; Kuhn W
    Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
    Spieth K; Kaufmann R; Gille J
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
    Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
    Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treosulfan as an effective second-line therapy in ovarian cancer.
    Gropp M; Meier W; Hepp H
    Gynecol Oncol; 1998 Oct; 71(1):94-8. PubMed ID: 9784326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
    Neuber K
    Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic effects of treosulfan on prostate cancer cell lines.
    Feyerabend S; Feil G; Krug J; Kassen A; Stenzl A
    Anticancer Res; 2007; 27(4B):2403-8. PubMed ID: 17695531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
    Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
    Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
    Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
    Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
    Lanvers-Kaminsky C; Bremer A; Dirksen U; Jürgens H; Boos J
    Anticancer Drugs; 2006 Jul; 17(6):657-62. PubMed ID: 16917211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
    Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
    Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
    Okumura S; Nishimura T; Yoshida K; Ohhara M; Hasegawa J; Hirasawa S; Hara M; Kawamura N; Kanamori S; Akimoto M
    Hinyokika Kiyo; 1984 Sep; 30(9):1167-71. PubMed ID: 6084420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.